Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVi
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
11:21am, Friday, 07'th Jun 2024
Data from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.
NEW YORK, NY / ACCESSWIRE / June 7, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVi
Top 2 dividend stocks to buy for long-term gains
09:06am, Friday, 07'th Jun 2024
Dividend stocks benefit from falling interest rates as money managers shift to income-oriented equities with yields above the S&P 500.
Focus: AbbVie's tight grip on Humira market raises concerns about biosimilars
06:06am, Friday, 07'th Jun 2024
AbbVie's top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine lower-priced rivals in the U.S. in the last year, raising questions about whether the market for pr
Final Trades: Amazon, Goldman Sachs, AbbVie and IQVIA Holdings
02:32pm, Thursday, 06'th Jun 2024
The Investment Committee give you their top stocks to watch for the second half.
AbbVie (ABBV) Starts Late-Stage Study on Multiple Myeloma Drug
12:56pm, Thursday, 06'th Jun 2024
The late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with relapsed/refractory multiple myeloma who have received at least two lines of prior therapy.
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
11:00am, Thursday, 06'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVi
AbbVie's ovarian cancer therapy succeeds in mid-stage trial
09:11am, Thursday, 06'th Jun 2024
AbbVie said on Thursday its therapy to treat patients with a type of ovarian cancer has met the main goal of a mid-stage trial.
PICCOLO trial met its primary endpoint of objective response rate (ORR) Data from the study will be presented at a future medical meeting NORTH CHICAGO, Ill. , June 6, 2024 /PRNewswire/ -- AbbVie (NY
SkinMedica® Celebrates 25 Years of Empowering Radiant Skin
08:30am, Thursday, 06'th Jun 2024
Allē Members Can Celebrate with Double Points and Enter for a Chance to Win $5,000 IRVINE, Calif. , June 6, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), the makers of BOT
AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their Careers
08:00am, Thursday, 06'th Jun 2024
The submission period is now open to individuals living with migraine for the new AbbVie Migraine Career Catalyst Award™ contest, awarding winners with a financial prize that they may decide to use
Hedge Fund Favorites: 7 Stocks to Buy When You're Feeling Jittery
06:00am, Thursday, 06'th Jun 2024
With the market entering a historically challenging season (due to the adage buy in May and go away), jittery investors may want to turn to stocks to buy tacitly endorsed by the hedge funds and other
Biotech Blockbusters: 3 Pharma Stocks to Buy in June for Breakthrough Potential
05:37pm, Wednesday, 05'th Jun 2024
The biotech sector has been through a lot in the past five years and it is finally rebounding. One of the most important sectors globally, it is hard to imagine life without biotech companies that pro
Calling All Cerevel Therapeutics Holdings, Inc. (CERE) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses
11:00am, Wednesday, 05'th Jun 2024
NEW YORK, NY / ACCESSWIRE / June 5, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Cerevel Therapeutics Holdings, Inc. ("Cerevel") (NASDAQ:CERE) and AbbVie, Inc. ("AbbVi
